Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CCR8 monoclonal antibody ABBV-514

An afucosylated monoclonal antibody directed against human C-C motif chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody ABBV-514 targets and binds to CCR8 on CCR8-positive, immunosuppressive tumor-infiltrating T-regulatory (TITR) cells in the tumor microenvironment (TME). This depletes CCR8-positive TITR cells via antibody-dependent cell-mediated cytotoxicity (ADCC), which may reverse the suppression of CD8+ effector T cells and reactivate antitumor immune responses. CCR8 is specifically expressed by TITR cells in multiple types of cancer and plays a key role in immunosuppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-C-C motif chemokine receptor 8 monoclonal antibody ABBV-514
anti-C-C-chemokine receptor 8 monoclonal antibody ABBV-514
Code name:ABBV 514
ABBV-514
ABBV514
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search